A group of tenants living in properties managed by ARHA recounted their abysmal living conditions and distrust of the organization to City Council.

AstraZeneca's Fasenra misses the primary COPD endpoint while Saphnelo's lupus trial shows significant improvements and ...

Every spring, most Americans dutifully adjust their clocks forward to daylight saving time, and every fall, back to standard ...

Saphnelo, which generated $304 million in sales in the first half of this year, is projected to achieve peak annual sales of ...

Among patients with COPD, at least 50% reported that the disease impacts their daily life and emotional health, according to ...

AstraZeneca said on Wednesday its asthma drug Fasenra failed to control the rate of flare-ups in patients with chronic ...

The likelihood for mortality during hospitalization was increased among those with COPD or asthma vs. asthma-COPD overlap ...

While there has been progress against chronic disease, the U.S. has been backsliding against big killers like heart disease.

In most countries, a slowdown in circulatory disease deaths drove the net decline in NCD mortality from 2010 to 2019. This ...

The American College of Chest Physicians (CHEST) and the American Lung Association (ALA) have awarded the CHEST/ALA Guideline ...

AstraZeneca (($AZN)) announced an update on their ongoing clinical study. AstraZeneca, in collaboration with Amgen, is ...

Chronic kidney disease (CKD) is a progressive condition in which the kidneys are damaged and can’t filter blood effectively. This can eventually lead to a buildup of waste and fluid in the body. In ...